

Attorney Docket No.: 5200.220-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Svendsen et al.

Confirmation No: 1715

Serial No.: 09/732,350

Group Art Unit: 1652

Filed: December 7, 2000

Examiner: K. Kerr

For: Laccase Mutants

FAX RECEIVED

NOV 08 2002

GROUP 1600

CERTIFICATE OF FACSIMILE TRANSMISSION

OFFICIAL

Commissioner for Patents
Washington, DC 20231


Sir:

I hereby certify that the attached correspondence comprising:

1. Amendment Fee Transmittal (in duplicate)
2. Amendment

was sent to the United States Patent and Trademark Office by telefax to the attention of Examiner K. Kerr, fax number (703) 308-0294.

Respectfully submitted,



Date: November 7, 2002

Lourdes Ayala
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097

Attorney Docket No.: 5200.220-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Svendsen et al.

Confirmation No: 1715

Serial No.: 09/732,350

Group Art Unit: 1652

Filed: December 7, 2000

Examiner: K. Kerr

For: Laccase Mutants

AMENDMENT FEE TRANSMITTALCommissioner for Patents
Washington, DC 20231

Sir:

Transmitted herewith is an Amendment for the above-identified application in response to the Office Action mailed May 7, 2002.

It is respectfully requested that the time for response to the Office Action be extended for a period of 3 months from August 7, 2002 to November 7, 2002. The required fee for the extension is estimated to be \$920.

The fee for claims has been calculated as shown below:

Total: $32 - 20 = 12 \times 18 = \216


Independent: $2 - 3 = 0 \times 84 = \$0$

Total additional fee for claims required is \$216.

Please charge the required extension and claims fees, estimated to be \$1,136, to Novozymes North America, Inc., Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: November 7, 2002


Elias J. Lambiris, Reg. No. 33,728
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097

#8/B
Drost
11-21-02

Attorney Docket No.: 5200.220-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Svendsen et al.

Confirmation No: 1715

Serial No.: 09/732,350

Group Art Unit: 1652

Filed: December 7, 2000

Examiner: K. Kerr

For: Laccase Mutants

AMENDMENT UNDER 37 C.F.R. 1.111Commissioner for Patents
Washington, DC 20231

Sir:

In response to the Office Action mailed May 7, 2002, please amend the above-identified application as follows:

IN THE CLAIMS:

Please cancel claims 11-18 without prejudice or disclaimer. Please add new claims 32-63:

32. A variant of a laccase having an amino acid sequence of SEQ ID NO: 10, wherein the variant has laccase activity and comprises one or more of the following mutations:

H93E;

H95E;

D106A,F,I,L,P,V,W,Y;

A108F,I,L,P,V,W,Y;

N109A,D,F,I,L,P,Q,V,W,Y;

T428A,F,I,L,P,V,W,Y;

M433E;

L500F,I,W,Y;

A506E;

S510A,F,I,L,P,V,W,Y;

G511F,I,L,P,V,W,Y; and

G514A,F,I,L,P,V,W,Y.

B1